| 書目名稱 | Pancreatic Cancer | | 副標(biāo)題 | Current Therapeutics | | 編輯 | Shubham Pant | | 視頻video | http://file.papertrans.cn/741/740692/740692.mp4 | | 概述 | Illuminates therapeutic advances in pancreatic cancer.Explains the incorporation of Next generation and germline sequencing in the care of patients.Provides the latest therapies that target tumor stro | | 圖書封面 |  | | 描述 | .?.Pancreatic cancer is?a?challenging?and?complex disease?characterized by a dense fibrotic stroma and an immunosuppressive tumor microenvironment.??Until recently, there were no predictive biomarkers to personalize selection of targeted or biologic therapies as a part of standard of care treatment. Moreover,?the?regulatory immune population of cells creates a “cold”, non-immunogenic tumor that is resistant?to?immunotherapies including checkpoint inhibitors. However, in the last few years, there has been substantial progress in our understanding of the role mutations in the pathogenesis of disease leading to increased adoption of germline and next generation sequencing to identify mutations and fusions to optimize selection of therapies and select patients for clinical trials of targeted agents..This book provides a comprehensive, global overview on?therapy for?pancreatic cancer, exploring?approved therapies?and focusing?on the “Next” in drug development including molecularly targeted therapy and efforts at “Drugging the Undruggable”: the KRAS mutation. It also addresses efforts at targeting the inhospitable stroma to improve drug delivery to the tumor cells, incorporating ct DNA ( | | 出版日期 | Book 2023 | | 關(guān)鍵詞 | Resection; Metastasis; immunotherapy; targeted therapy; adjuvant treatment; neoadjuvant treatment; microbi | | 版次 | 1 | | doi | https://doi.org/10.1007/978-3-031-38623-7 | | isbn_softcover | 978-3-031-38625-1 | | isbn_ebook | 978-3-031-38623-7 | | copyright | The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl |
The information of publication is updating
|
|